

What Are the Current Treatment Patterns for Patients With Newly Diagnosed PAH in the Pulmonary Hypertension Association Registry?


STUDY DESIGN

Observational analysis of US-based, prospective, multicenter Pulmonary Hypertension Association Registry from 2015 to 2024

- Assess **real-world treatment patterns** of pulmonary arterial hypertension (PAH) compared with guideline-directed treatment
- Compare **all-cause mortality** across risk strata

RESULTS

Initial treatment for 1,019 patients with incident PAH



Risk stratification by low-, intermediate-, and high-risk PAH (REVEAL Lite 2)

Monotherapy (n = 323)

25.1% low, 31.3% intermediate, 43.7% high

Dual therapy (n = 540)

35.7% low, 26.5% intermediate, 37.8% high

Triple therapy (n = 113)

31.9% low, 28.3% intermediate, 39.8% high



All-cause mortality was ↓ low-risk PAH at baseline and ↑ high-risk PAH at baseline

- Across the entire cohort
- Among those receiving monotherapy or dual therapy

In this study, real-world data indicate that there are substantial deviations in clinical practice from the current guidelines for treating incident PAH.